These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 33657663)

  • 1. Integrated molecular modeling techniques to reveal selective mechanisms of inhibitors to PI3Kδ with marketed Idelalisib.
    Zhu J; Jia L; Jiang Y; Yu Q; Xu L; Cai Y; Chen Y; Li H; Gang H; Liang W; Jin J
    Chem Biol Drug Des; 2021 Jun; 97(6):1158-1169. PubMed ID: 33657663
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Theoretical studies on the selectivity mechanisms of PI3Kδ inhibition with marketed idelalisib and its derivatives by 3D-QSAR, molecular docking, and molecular dynamics simulation.
    Zhu J; Ke K; Xu L; Jin J
    J Mol Model; 2019 Jul; 25(8):242. PubMed ID: 31338599
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel 6-aryl substituted 4-pyrrolidineaminoquinazoline derivatives as potent phosphoinositide 3-kinase delta (PI3Kδ) inhibitors.
    Xin M; Duan W; Feng Y; Hei YY; Zhang H; Shen Y; Zhao HY; Mao S; Zhang SQ
    Bioorg Med Chem; 2018 May; 26(8):2028-2040. PubMed ID: 29534936
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural, biochemical, and biophysical characterization of idelalisib binding to phosphoinositide 3-kinase δ.
    Somoza JR; Koditek D; Villaseñor AG; Novikov N; Wong MH; Liclican A; Xing W; Lagpacan L; Wang R; Schultz BE; Papalia GA; Samuel D; Lad L; McGrath ME
    J Biol Chem; 2015 Mar; 290(13):8439-46. PubMed ID: 25631052
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular dynamics insights for PI3K-δ inhibition & structure guided identification of novel PI3K-δ inhibitors.
    Srivastava S; Singh Choudhary B; Mehta P; Sukanya ; Sharma M; Malik R
    J Biomol Struct Dyn; 2019 Jun; 37(9):2404-2414. PubMed ID: 30047836
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and biological evaluation of novel purinyl quinazolinone derivatives as PI3Kδ-specific inhibitors for the treatment of hematologic malignancies.
    Kim YS; Cheon MG; Boggu PR; Koh SY; Park GM; Kim G; Park SH; Park SL; Lee CW; Kim JW; Jung YH
    Bioorg Med Chem; 2021 Sep; 45():116312. PubMed ID: 34332211
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and biological evaluation of 4-(piperid-3-yl)amino substituted 6-pyridylquinazolines as potent PI3Kδ inhibitors.
    Feng Y; Duan W; Fan S; Zhang H; Zhang SQ; Xin M
    Bioorg Med Chem; 2019 Oct; 27(19):115035. PubMed ID: 31434616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of triazole aminopyrazines as a highly potent and selective series of PI3Kδ inhibitors.
    Terstiege I; Perry M; Petersen J; Tyrchan C; Svensson T; Lindmark H; Öster L
    Bioorg Med Chem Lett; 2017 Feb; 27(3):679-687. PubMed ID: 28017532
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PI3Kδ inhibitors for the treatment of cancer: a patent review (2015-present).
    Feng Y; Cu X; Xin M
    Expert Opin Ther Pat; 2019 Dec; 29(12):925-941. PubMed ID: 31670985
    [No Abstract]   [Full Text] [Related]  

  • 10. PI3Kδ inhibitor idelalisib in combination with BTK inhibitor ONO/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3Kδ and BTK inhibitors.
    Yahiaoui A; Meadows SA; Sorensen RA; Cui ZH; Keegan KS; Brockett R; Chen G; Quéva C; Li L; Tannheimer SL
    PLoS One; 2017; 12(2):e0171221. PubMed ID: 28178345
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Idelalisib inhibits osteoclast differentiation and pre-osteoclast migration by blocking the PI3Kδ-Akt-c-Fos/NFATc1 signaling cascade.
    Yeon JT; Kim KJ; Son YJ; Park SJ; Kim SH
    Arch Pharm Res; 2019 Aug; 42(8):712-721. PubMed ID: 31161369
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SAF-248, a novel PI3Kδ-selective inhibitor, potently suppresses the growth of diffuse large B-cell lymphoma.
    Zhang X; Duan YT; Wang Y; Zhao XD; Sun YM; Lin DZ; Chen Y; Wang YX; Zhou ZW; Liu YX; Jiang LH; Geng MY; Ding J; Meng LH
    Acta Pharmacol Sin; 2022 Jan; 43(1):209-219. PubMed ID: 33782541
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of novel quinazolinone derivatives as high potent and selective PI3Kδ and PI3Kδ/γ inhibitors.
    Ma CC; Zhang CM; Tang LQ; Liu ZP
    Eur J Med Chem; 2018 May; 151():9-17. PubMed ID: 29601991
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bioisosteric replacements of the indole moiety for the development of a potent and selective PI3Kδ inhibitor: Design, synthesis and biological evaluation.
    Yang C; Xu C; Li Z; Chen Y; Wu T; Hong H; Lu M; Jia Y; Yang Y; Liu X; Deng M; Chen Z; Li Q; Ling Y; Zhou Y
    Eur J Med Chem; 2021 Nov; 223():113661. PubMed ID: 34237636
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploring PI3Kγ binding preference with Eganelisib, Duvelisib, and Idelalisib via energetic, pharmacophore and dissociation pathway analyses.
    Jia L; Wang L; Jiang Y; Xu L; Cai Y; Chen Y; Jin J; Sun H; Zhu J
    Comput Biol Med; 2022 Aug; 147():105642. PubMed ID: 35635904
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Idelalisib activates AKT via increased recruitment of PI3Kδ/PI3Kβ to BCR signalosome while reducing PDK1 in post-therapy CLL cells.
    Mamidi MK; Mahmud H; Maiti GP; Mendez MT; Fernandes SM; Vesely SK; Holter-Chakrabarty J; Brown JR; Ghosh AK
    Leukemia; 2022 Jul; 36(7):1806-1817. PubMed ID: 35568768
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and Evaluation of Novel 2H-Benzo[e]-[1,2,4]thiadiazine 1,1-Dioxide Derivatives as PI3Kδ Inhibitors.
    Gong YP; Tang LQ; Liu TS; Liu ZP
    Molecules; 2019 Nov; 24(23):. PubMed ID: 31775363
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SAR study of 5-alkynyl substituted quinazolin-4(3H)-ones as phosphoinositide 3-kinase delta (PI3Kδ) inhibitors.
    Wei M; Zhang X; Wang X; Song Z; Ding J; Meng LH; Zhang A
    Eur J Med Chem; 2017 Jan; 125():1156-1171. PubMed ID: 27846451
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of Novel PI3Kδ Selective Inhibitors by SVM-Based Multistage Virtual Screening and Molecular Dynamics Simulations.
    Liang JW; Wang S; Wang MY; Li SL; Li WQ; Meng FH
    Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31795217
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Homeostatic and pathogenic roles of PI3Kδ in the human immune system.
    Sogkas G; Adriawan IR; Dubrowinskaja N; Atschekzei F; Schmidt RE
    Adv Immunol; 2020; 146():109-137. PubMed ID: 32327151
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.